Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs
This article was originally published in RPM Report
Executive Summary
FDA's new drug safety authorities suggest that the focus of drug development and lifecycle management strategies need to change. It is no longer a question of what it takes to get approval from FDA, but rather what kind of approval you can get.